研究

Sakurai M, Arai Y, Goto H, Kim H, Masuda K, Kitawaki T, Fujii N, Shimoyama T, Yoshihara S, Kato J, Ara T, Terakura S, Umezawa Y, Nakazawa H, Ando M, Shimura Y, Kanemura N, Onodera K, Nakashima Y, Tanaka H, Atsuta Y, Kataoka K, Kato K.

Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: a nationwide registry.

Yoshimitsu M, Itonaga H, Kato K, Tokunaga M, Fujioka M, Uchida N, Mori Y, Itoh A, Serizawa K, Eto T, Yonezawa A, Uehara Y, Endo S, Ishitsuka K, Kanda Y, Fukuda T, Atsuta Y, Fuji S.

Second Allogeneic Hematopoietic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma: A Nationwide Registry Analysis.

Lee JW, Jang JH, Yamazaki H, Sawa M, Kizaki M, Tomiyama Y, Nagafuji K, Usuki K, Gau JP, Morita Y, Tang JL, Chang H, Noshiro M, Matsuda A, Ozawa K, Mitani K, Kanda Y, Nakao S.

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia

Satake A, Nagate Y, Miyawaki K, Fujiwara Y, Ota S, Muta T, Rai S, Tsurumi H, Suzuki R, Miyake T, Goto H, Fukuhara N, Sakata-Yanagimoto M, Izutsu K, Nishikori M, Shibayama H, Kumode T, Ennishi D, Shimose T, Inubashiri N, Matsumura I, Akashi K, Kato K.

Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR).

Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trněný M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Batlevi CL, Tilly H, Flowers CR.

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

Rai S, Tanizawa Y, Terasawa T, Tajimi M, Ideue R, Burlison H, Milloy N, Simpson A, Taipale KL, Jen MH, Segall G, Goebel B, Kiran A.

Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study

Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Kada A, Saito AM, Shimoda K, Sugimoto Y, Kurokawa T, Tomita A, Edahiro Y, Kiyoi H, Akashi K, Matsumura I, Takenaka K, Komatsu N.

Post-Diagnosis Hemorrhagic Events Are Strongly Associated With Poor Survival in Patients With Essential Thrombocythemia

Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, Nishikori M, Kumode T, Suehiro Y, Ishitsuka K, Conlon R, Takahashi A, D'Angelo Månsson B, Favaro E, Fukuhara N.

Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial

Jang JH, Mitani K, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Murotani K, Shimizu M, Matsuda A, Ozawa K, Nakao S, Lee JW.

Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials

Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Jafarinasabian P, Soong D, D'Angelo Månsson B, Takahashi A, Favaro E, Fukuhara N.

Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial

Takahashi N, Kikushige Y, Nakamae H, Goto T, Tomita A, Ichii M, Ito S, Teshima T, Kirito K, Ikezoe T, Hatano K, Tanaka H, Hiramoto N, Osako R, Aoki M, Malek K, Ueda Y

Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST

Kawamura S, Nakagawa D, Nagayama T, Katayama Y, Doki N, Takeda W, Nishida T, Matsuoka KI, Ikeda T, Ohigashi H, Sawa M, Fukushima K, Kanda J, Serizawa K, Onizuka M, Fukuda T, Atsuta Y, Kanda Y, Nakasone H.

Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT

Shinohara A, Shindo M, Yamasaki S, Kato K, Yoshihara S, Yamamoto G, Kataoka K, Ikeda T, Kobayashi H, Serizawa K, Mori Y, Takayama N, Nakazawa H, Ito A, Katayama Y, Kanda Y, Yoshimitsu M, Fukuda T, Atsuta Y, Kondo E.

Fludarabine Plus Myeloablative Dose of Busulfan Regimen Was Associated with High Nonrelapse Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Lymphoma: A Propensity Score-Matched Comparison Study with Fludarabine Plus High-Dose Melphalan

Makishima H, Mikasa T, Isogaya K, Miyamoto T, Yamauchi T, Yokota A, Onozawa M, Ando K, Ogawa Y, Usuki K, Yamauchi T, Ota S, Takada S, Morita Y, Ishikawa T, Takenaka K, Kuroda J, Sekiguchi N, Kawakita T, Miyazaki Y.

Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351

Chang C, Suzuki T, Liang Y, Tong H, Usuki K, Liu Q, Wu Y, Fujisaki T, Han B, Huang R, Morita Y, Miao M, Nakashima Y, Tian YO, Pu J, Aggarwal D, Pozharskaya V, Shi W, Xiao Z, Mitani K.

Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging study

Yoshimitsu M, Choi I, Kusumoto S, Shimokawa M, Utsunomiya A, Suehiro Y Dr, Hidaka T, Nosaka K, Sasaki H, Rai S, Tamura S, Owatari S, Koh KR, Nakamura D, Tokunaga M, Sekine M, Sakamoto Y, Inagaki H, Ishida T, Ishitsuka K.

A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma

Okayama Y, Takakuwa T, Shimura Y, Imada K, Kosugi S, Hotta M, Fuchida SI, Tanaka H, Uoshima N, Yoshihara S, Kanda J, Shibayama H, Fukushima K, Ohta K, Yagi H, Ito T, Shimazaki C, Matsumura I, Takaori-Kondo A, Hosen N, Hino M, Kuroda J.

Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum

Munakata W, Kumode T, Goto H, Fukuhara N, Shimoyama T, Takeuchi M, Kawakita T, Kubo K, Sawa M, Uchida T, Mishima Y, Ichii M, Hanaya M, Matsumoto A, Kuriki M, Seike T, Izutsu K, Ishizawa K.

A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study

Shinohara A, Shindo M, Nakano N, Sakaida E, Uchida N, Fukushima K, Nakazawa H, Serizawa K, Kanda Y, Kawakita T, Ikeda T, Ohigashi H, Ito A, Wakayama T, Matsuoka KI, Fukuda T, Tanaka J, Atsuta Y, Nakasone H

Increased Non-Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan-Based Regimen

Goto H, Kumode T, Mishima Y, Kataoka K, Ogawa Y, Kanemura N, Shimada K, Uchida T, Kuroe Y, Kawasaki A, Sato J, Teshima T.

Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1

Muta T, Masamoto Y, Yamamoto G, Kurahashi S, Kameoka Y, Ota S, Matsuki E, Ozeki K, Toyama T, Takahashi N, Kumode T, Aotsuka N, Yoshimura T, Tamura H, Omi A, Shibayama K, Watanabe A, Isobe Y, Kojima K, Takizawa J, Nagai H, Suzumiya J, Aoki S

Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study

Kosugi H, Fujisaki T, Iwasaki H, Shinagawa A, Iida H, Jo T, Kubonishi S, Morita Y, Nakashima Y, Onodera K, Suzuki K, Suzuki T, Tamai Y, Usuki K, Yokota A, Yonaga H, Hayakawa J, Midorikawa S, Nishio M, Suda M, Matsue K.

A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes

The Terry Fox Research Institute Marathon of Hope Cancer Centers Network

The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Hayakawa F, Mori N, Imai K, Yokoyama Y, Katsuoka Y, Saito T, Murayama T, Yamazaki E, Sato S, Atsuta Y, Ishikawa Y, Sakaida E, Hatta Y, Matsumura I, Miyazaki Y, Kiyoi H; Japan Adult Leukemia Study Group (JALSG).

Nelarabine-combined chemotherapy improves outcome of T-cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T-ALL213-O.

Fukui-Morimoto A, Serizawa K, Fujimoto K, Hanamoto A, Iwata Y, Kakutani H, Kumode T, Hirase C, Morita Y, Tatsumi Y, Hanamoto H, Tanaka H, Matsumura I.

CD34+ and CD34- MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34+ MM cells

Yuji Nozaki1, Kazuya Kishimoto1, Tetsu Itami1, Daisuke Tomita11, Yumiko Wada2, Takuya Kotani2, Tohru Takeuchi2, Toshihiko Hidaka3, Shoichi Hino4, Toshiaki Miyamoto5,6, Hirofumi Miyake7, Kazunari Hatta7, Kenji Mamoto8, Yutaro Yamada9, Tadashi Okano9, Takaichi Okano10, Jun Saegusa10, Masahiro Horita11, Keiichiro Nishida12, Koji Kinoshita1, Shinya Rai1,13

Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis

Yuji Nozaki1*, Koichi Murata2, Akira Onishi2, Kohei Tsujimoto3, Wataru Yamamoto4, Hirotaka Yamada5, Sho Sendo5, Motomu Hashimoto6, Tadashi Okano7, Hideyuki Shiba8, Yuri Hiramatsu8, Yonsu Son9, Naofumi Yoshida9, Rika Fukuda1, Yumi Morimoto1, Kazuya Kishimoto1, Tetsu Itami1, Daisuke Tomita1, Chisato Ashida1, Toshihiko Shiga1, Koji Kinoshita1

Clinical Efficacy of JAK Inhibitors for Rheumatoid Arthritis Patients with Poor-Prognosis Factors: The ANSWER Cohort Study

Yuji Nozaki*, Kazuya Kishimoto, Daisuke Tomita, Tetsu Itami, Chisato Ashida, Toshihiko Shiga, Hirotaka Yamazawa, Kaori Ishimura, Yumi Morimoto, Rika Fukuda, and Koji Kinoshita

Stepwise Dose Reduction and Discontinuation of bDMARD in Rheumatoid Arthritis: A Prospective Cohort Study of Flare-Free Population, Flares, and Predictive Markers